The pipeline of next-generation treatments is advancing rapidly: Novo Nordisks CagriSema, a fixed-dose combination of semaglutide and the amylin analogue cagrilintide, has an FDA decision expected in late 2026 and could further accelerate the market
TABLE 1 Summary of case reports of GLP-1 receptor agonists-induced acute pancreatitis reported in the literature
Ninety-five percent of GLP-1 users report eating smaller portions, and 87% are snacking less, and 81% are eating less frequentlysignaling a significant shift in eating habits among users
Microdosing can deliver comparable outcomes to regular dosing, particularly for individuals focusing on gradual and sustainable weight loss, as well as enhanced metabolic health
She has a Bachelors of Science in Biomedical Science from Oakland University in Auburn Hills, Michigan
November 22, 2024: Researchers Ramp Up Warnings About Ozempics Cancer Risks to Patients Researchers continue to caution patients and medical professionals about the increased risks of using Ozempic, a glucagon-like peptide 1 (GLP-1) receptor agonist
